Recalibrating intellectual property rights to enhance translational research collaborations

Tania Bubela, Garret A. FitzGerald, E. Richard Gold

Research output: Contribution to journalComment/debate

24 Citations (Scopus)


Multisectoral collaborative models for drug and therapeutic research and development (R&D) are emerging, requiring a recalibration of how intellectual property rights (IPRs) are used. Although these models appear promising, little study has been conducted on the optimal blend of sharing and exclusion as mediated through the proactive use or nonuse of IPRs. This Commentary is a call for a combination of theoretical and empirical analyses to build a comprehensive understanding of the interplay between formal IP laws, institutions that administer and manage IPRs, and the use of IPRs in practice to better construct and manage collaborations. Such analyses require outcome metrics formulated to measure the success of therapeutic outcomes and to capture the complexity of a highly networked R&D environment.

Original languageEnglish
Article number122cm3
JournalScience Translational Medicine
Issue number122
Publication statusPublished - 22 Feb 2012
Externally publishedYes


Dive into the research topics of 'Recalibrating intellectual property rights to enhance translational research collaborations'. Together they form a unique fingerprint.

Cite this